echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clinical efficacy of alvartrombopag compared with recombinant human thrombopoietin in the treatment of severe thrombocytopenia associated with chronic liver disease: a real-world clinical study

    Clinical efficacy of alvartrombopag compared with recombinant human thrombopoietin in the treatment of severe thrombocytopenia associated with chronic liver disease: a real-world clinical study

    • Last Update: 2022-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The first medical video of "Xinsu" invited Professor Wang Jizhou, Department of Hepatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, to explain the clinical study
    of chronic liver disease (CLD)-related severe thrombocytopenia (TCP) recently published in Frontiers in Pharmacology.
    At the same time, we also invited
    Professor Liu Lianxin from the First Affiliated Hospital of the University of Science and Technology of China to introduce the clinical background
    of the team's research to us.

    The following is the full video of Professor Liu Lianxin and Professor Wang Jizhou interpreting the literature:


    Prognosis of patients with chronic liver disease-related thrombocytopenia










    Chronic liver disease (CLD) is a significant and underestimated public health burden
    associated with high mortality.
    Worldwide, 844 million people suffer from chronic liver disease, with a mortality rate
    of up to 2 million per year.
    The progression of chronic liver disease to liver fibrosis, end-stage cirrhosis, liver failure, and hepatocellular carcinoma is closely related
    to increased patient morbidity, frequency of hospitalization, and deterioration of quality of life.
    Thrombocytopenia (TCP), the most common complication of chronic liver disease, affects up to 76% of patients with
    advanced liver fibrosis or cirrhosis.
    Decreased production of thrombopoietin (TPO) by the liver and direct bone marrow suppression are the main mechanisms
    .


    In addition, as liver disease progresses, patients often require more frequent invasive procedures such as endoscopic biopsy, percutaneous biopsy, surgical radiofrequency ablation, or hepatectomy
    .
    Many patients, especially those with chronic liver disease with severe thrombocytopenia (TCP), have low platelet counts that prevent them from undergoing the necessary surgery to improve survival or improve their quality of life
    .



    Current status of drug treatment for thrombocytopenia associated with chronic liver disease







    For these patients undergoing invasive procedures, platelet transfusions are often used
    clinically.
    However, the use of platelet transfusions may be limited
    by the production of antiplatelet antibodies, high cost, short shelf life, risk of infection, and other transfusion-related complications.
    Recombinant human thrombopoietin (rhTPO) Although some clinically centers still use rh-TPO to treat CLD combined with TCP, rhTPO has no indication for CLD-related thrombocytopenia in China; As a novel oral TPO-RA, avartrombopag has been approved as an alternative to platelet transfusion in adult patients
    with chronic liver disease-associated thrombocytopenia undergoing elective diagnostic procedures or surgery.



    The theme of this issue of "Shin Express"







    This issue is a retrospective study that is the world's first real-world clinical study
    comparing the efficacy and safety of oral avatrombopag and subcutaneous rh-TPO.
    The study retrospectively analyzed the clinical data
    of 237 patients with severe TCP associated with chronic liver disease admitted to the First Affiliated Hospital of University of Science and Technology of China from January 2019 to January 2022.
    The clinical efficacy
    of arvarotrombopag and recombinant human thrombopoietin in the treatment of severe thrombocytopenia associated with chronic liver disease was compared using statistical analysis methods for propensity score matching.


    The results show:

    1.
    Atvartrombopag is significantly more effective than rh-TPO in the treatment of Child-Pugh Class A CLD-related TCP, and the incidence of dizziness is lower
    .

    2.
    Whether it is oral form of avarambopag or subcutaneous injection form of rh-TPO, the efficacy in the treatment of PLTs > 25×10 9/L is higher
    than that of PLTs < 25×109/L.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.